Genitourinary Cancer, Prostate Cancer
Read Time: 3 mins

Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? In Favour

Copy Link
Published Online: May 14th 2018 European Oncology & Haematology, 2018;14(1):12–13 DOI:
Authors: Hendrik Van Poppel
Quick Links:
Article Information

With the introduction of new anatomical and functional imaging modalities, mainly positron emission tomographycomputed tomography (PET-CT) and multi-parametric magnetic resonance imaging, the eventual origin of biochemical recurrence after curative treatment for prostate cancer can be detected at its earliest stage. Targeted treatment strategies to this local or oligometastatic relapse will be successful in postponing the initiation of systemic treatment, thereby delaying the occurrence of the castrate resistant state and, eventually, improve survival.


Biochemical recurrence, prostate-specific antigen, PSA recurrence, prostatespecific membrane antigen, PSMA, MRI, oligometastasis, prostate cancer, recurrence


Approximately 15–40% of men will develop recurrent disease following an attempt at curative therapy for prostate cancer. Some of them will develop metastases after a median time of 8–10 years. The predictors of metastasis are Gleason score of 8–10, pathological stage T3b-4, nodal invasion and prostate-specific antigen (PSA) doubling time. One can anticipate that about 10% of patients with recurrent PSA will develop systemic progression and that 5% will die from prostate cancer more than 10 years after radical prostatectomy and more than 6 years after the biochemical recurrence.1

In the investigation of PSA recurrence after radical prostatectomy, conventional imaging (bone scan and computed tomography [CT]) has low sensitivity and accuracy, but nowadays we have at our disposal a combination of anatomical and functional imaging with choline or prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-CT and multi-parametric magnetic resonance imaging (MRI). These imaging tools are able to detect the origin of the PSA relapse either in the bone or in the nodes, and hence are offering to prostate cancer experts a tool to detect oligometastatic disease, even at very low PSA levels when the PSA doubling time is short. The oligometastatic status (≤3–5 metastatic sites) is obviously less aggressive than other metastatic genotypes and a different micro RNA profile was described between oligometastatic and polymetastatic disease. When untreated, oligometastatic disease will progress locally and metastasis-directed treatment (MDT) may delay or prevent castration-resistant prostate cancer by eradicating castration-resistant clones. Metastasis-directed treatment might thus postpone the initiation of androgen deprivation therapy (with its documented toxicity) and – hypothetically – may lead to improved survival.

After an initial report by Rigatti et al.2 about salvage pelvic lymph node dissection in low volume metastatic recurrence and another about salvage external beam radiotherapy in hormone-naïve oligometastatic prostate cancer by Berkovic et al.,3 a number of series have been reported on both treatment strategies for oligometastatic disease detected with the novel imaging.4 In a systematic review, salvage lymphadenectomy was shown to yield 5-year biochemical progression-free survival rates in around 30% of patients and 5-year cancer specific survival rates of more than 80%. These excellent results are obtained in a selected group of patients with, preferably, a PSA below 4, a Gleason score below 8 and with pelvic node involvement only. Probably a template dissection is needed since even the best PET imaging today underestimates the extent of nodal invasion. From a meta-analysis on 450 patients treated with metastases-directed therapy for regional and distant recurrences after curative treatment of prostate cancer it was obvious that this approach with either radiotherapy or surgery is promising but still needs validation with a randomised controlled trial.5

Recently however, a randomised phase II trial of 62 patients was published in the Journal of Clinical Oncology.6 The STOMP trial (Surveillance or MDT for OligoMetastatic Prostate cancer recurrence) included patients with biochemical recurrence after radical prostatectomy or radiotherapy or both. They had three or fewer extra-cranial metastases on PET-CT. They were randomised for active surveillance with delayed androgen deprivation therapy (ADT) or MDT. The ADT free survival was 21 months after MDT and 13 months after active surveillance. The toxicity of MDT was very limited and, interestingly, the patients in the MDT arm were more advanced so that the beneficial effect might even have been underestimated.

The newer imaging techniques have changed our concept of prostate cancer metastatic disease as a stage that obviously deserves ADT. Early ADT decreases quality of life, induces metabolic syndrome, never brings cure and does not prolong survival, while MDT will at least postpone ADT and could cure 20–30% of these cases.7 With optimal early imaging, we will detect oligometastases more often and at a stage where cure is indeed not exceptional. There is therefore no reason today to delay imaging in PSA recurrent patients even at very low PSA values when the PSA doubling time is short.

Article Information:

Hendrik Van Poppel has nothing
to disclose in relation to this article.

Review Process

This editorial is based on a debate held at the European Association of Nuclear Medicine (EANM) Focus 1 meeting, Valencia, Spain, 1–3 February 2018 and, as such, has not been subject to this journal’s usual peer-review process. The report was reviewed for scientific accuracy by the journal’s Editorial Board before
Compliance with Ethics :This editorial involves a
review of the literature and did not involve any studies
with human or animal subjects performed by
any of the authors.


All named authors meet the criteria of
the International Committee of Medical Journal Editors
for authorship for this manuscript, take responsibility
for the integrity of the work as a whole and have
given final approval for the version to be published.


Hendrik Van Poppel, University
Hospital Gasthuisberg, Katholieke Universiteit Leuven,
Herestraat 49, 3000 Leuven, Belgium.


No funding was received in the publication of this article.


This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original
author(s) and source are given appropriate credit.




  1. Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59:893–9.
  2. Rigatti P, Suardi N, Briganti A, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43.
  3. Berkovic P, De Meerleer G, Delrue I, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2012;11:27–32.
  4. Abdollah F, Briganti A, Montorsi F, et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol. 2015;67:839–49.
  5. Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67:852–63.
  6. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.
  7. Van Poppel H, De Meerleer G, Joniau S. Oligometastatic prostate cancer: metastases-directed. Arab J Urol. 2016;14:179–82.

Further Resources

Share this Article
Related Content In Prostate Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72